Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Lung Cell Mol Physiol ; 302(11): L1150-8, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-22345575

ABSTRACT

Diminished Na,K-ATPase expression has been reported in several carcinomas and has been linked to tumor progression. However, few studies have determined whether Na,K-ATPase function and expression are altered in lung malignancies. Because cigarette smoke (CS) is a major factor underlying lung carcinogenesis and progression, we investigated whether CS affects Na,K-ATPase activity and expression in lung cell lines. Cells exposed to CS in vitro showed a reduction of Na,K-ATPase activity. We detected the presence of reactive oxygen species (ROS) in cells exposed to CS before Na,K-ATPase inhibition, and neutralization of ROS restored Na,K-ATPase activity. We further determined whether Na,K-ATPase expression correlated with increasing grades of lung adenocarcinoma and survival of patients with smoking history. Immunohistochemical analysis of lung adenocarcinoma tissues revealed reduced Na,K-ATPase expression with increasing tumor grade. Using tissue microarray containing lung adenocarcinomas of patients with known smoking status, we found that high expression of Na,K-ATPase correlated with better survival. For the first time, these data demonstrate that CS is associated with loss of Na,K-ATPase function and expression in lung carcinogenesis, which might contribute to disease progression.


Subject(s)
Adenocarcinoma/enzymology , Lung Neoplasms/enzymology , Nicotiana , Smoke/adverse effects , Sodium-Potassium-Exchanging ATPase/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma of Lung , Cell Line, Tumor , Disease Progression , Disease-Free Survival , Humans , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Neoplasm Grading , Reactive Oxygen Species/metabolism , Smoking/adverse effects , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Sodium-Potassium-Exchanging ATPase/biosynthesis
2.
Arch Pathol Lab Med ; 129(5): e117-20, 2005 May.
Article in English | MEDLINE | ID: mdl-15859655

ABSTRACT

Ectopic decidua is one of several benign lymph node inclusions that have been increasingly documented in the literature, most often in postmortem examinations of pregnant woman and recently in pregnant women with cervical squamous cell carcinoma. Although lacking clinical significance of its own, the major diagnostic implication would be misdiagnosis as metastatic carcinoma in the lymph node. Intraoperative frozen sections are often performed prior to radical hysterectomy, leading to a potential alteration of therapy if metastatic carcinoma is identified in the lymph nodes. We report such a case of a pregnant woman with cervical squamous cell carcinoma requiring lymphadenectomy and hysterectomy, in which the intraoperative frozen section of a pelvic lymph node with ectopic decidual change was mistakenly identified as metastatic carcinoma. Its histologic resemblance to carcinoma and location within subcapsular sinuses, compounded with the fact that ectopic lymph node decidua is not commonly seen in routine practice, can lead to this diagnostic pitfall. We review the literature regarding ectopic decidua, its presence in lymph nodes, and its pathogenesis, as well as review the literature on benign lymph node inclusions.


Subject(s)
Choristoma/pathology , Decidua , Lymph Nodes , Lymphatic Diseases/pathology , Pregnancy Complications, Neoplastic/pathology , Adult , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/secondary , Choristoma/surgery , Diagnosis, Differential , Female , Humans , Hysterectomy , Lymph Node Excision , Lymphatic Diseases/surgery , Lymphatic Metastasis/pathology , Pelvis , Pregnancy , Treatment Outcome , Uterine Cervical Neoplasms/diagnosis
3.
Nutr Cancer ; 49(1): 59-65, 2004.
Article in English | MEDLINE | ID: mdl-15456636

ABSTRACT

Many laboratory-based studies have shown that soy can suppress breast cancer proliferation. However, given the recent controversy generated by animal experiments that soy may under certain conditions stimulate breast cancer growth, we decided to carry out a pilot clinical trial in order to elucidate any interaction(s) between short-term isoflavone supplement administration and breast cancer growth. After a core-needle biopsy established the diagnosis of breast cancer, 17 patients were administered soy isoflavone tablets for two weeks. This surgically based study provided the unique opportunity to make objective observations based on human breast cancer tissues and blood obtained prior to and after isoflavone supplement treatment in the same patient. Twenty-six historical control cases with similar characteristics to the experimental patients were selected for comparison. We observed that the apoptosis/mitosis ratios in isoflavone-treated cancer specimens were not significantly different from those of control untreated cancer specimens. Furthermore, there appeared to be a statistically nonsignificant trend towards cancer growth inhibition in the isoflavone treatment group, as manifested by higher apoptosis/mitosis ratios compared with those from the control untreated group. Ex vivo/in vitro assays using serum from breast cancer patients prior to and at the conclusion of soy treatment reveal no significant proliferative changes on both breast cancer cells and endothelial cells. We concluded that the effect of soy on breast cancer deserves further studies in larger clinical trials.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/prevention & control , Cell Division/drug effects , Glycine max/chemistry , Isoflavones/therapeutic use , Adult , Aged , Aged, 80 and over , Biopsy, Needle , Breast Neoplasms/blood , Breast Neoplasms/pathology , Breast Neoplasms/urine , Dietary Supplements , Female , Humans , Middle Aged , Pilot Projects
SELECTION OF CITATIONS
SEARCH DETAIL
...